Deucravacitinib reduces circulating proteins associated with kidney dysfunction in patients with systemic lupus erythematosus, according to data presented at ACR Convergence 2025.“Specific plasma ...

Please provide your email address to receive an email when new articles are posted on . Patients with juvenile-onset lupus had significantly higher levels of apoptotic lymphocytes in peripheral blood.

Merck, a leading science and technology company, today announced positive data on enpatoran, an investigational, oral, novel TLR7/8 inhibitor, demonstrating clinically meaningful reduction in disease ...

One of Merck KGaA’s leading immunology assets has flunked the latest part of a phase 2 lupus trial. Despite the primary endpoint miss, Merck has concluded further development is warranted in light of ...